Furthermore, it contributes to the pathogenesis of diseasessuch as prostate cancer, polycystic ovary syndrome, and breast cancer.1,2 In view of this, extensive interest and effort have been put intothe discovery of compounds that regulate the activity of CYP17A1,with one of the specific aims to find drugs useful in the treatmentof castration-resistant prostate cancer. This evidence concerns the gene CYP17A1 and breast carcinoma.